Design and in vivo characterization of kidney-targeting multimodal micelles for renal drug delivery
- 526 Downloads
One in three Americans is at risk for developing chronic kidney disease (CKD) and end-stage renal disease (ESRD), leading to the need for dialysis or a kidney transplant. Small-molecule drugs have been proposed as therapies to manage kidney diseases, but high dosages are often required to achieve therapeutic efficacy, generating off-target side effects, some of which are lethal. To address these limitations, we developed a novel, kidney-targeting multimodal micelle (KM) system for drug delivery applications. Specifically, we incorporated the kidney-targeting peptide (Lysine-Lysine-Glutamic acid-Glutamic acid-Glutamic acid)3-Lysine) ((KKEEE)3K) into micelles. This peptide binds to megalin, a multi-ligand cell surface receptor present on renal tubule cells. When incubated with human kidney proximal tubule cells, KMs were found to be biocompatible in vitro. In vivo, KMs showed higher accumulation in the kidneys as compared to a non-targeted (NT) control upon intravenous injection in wild-type C57BL/6J mice. Histological evaluation showed no signs of tissue damage, while blood urea nitrogen (BUN) and creatinine levels were within normal ranges, validating the preservation of kidney health upon micelle administration. To our knowledge, this is the first utilization of (KKEEE)3K in a nanoparticle formulation, and our study offers strong evidence that this novel nanoparticle platform can be used as a candidate drug delivery carrier to direct therapeutics to diseased tissue in CKD.
Keywordsmicelle kidney disease renal targeting biodistribution nanoparticle
Unable to display preview. Download preview PDF.
The authors would like to acknowledge the financial support from the University of Southern California (USC) Provost Fellowship awarded to J. W., the National Heart, Lung, and Blood Institute (NHLBI), R00HL124279 awarded to E. J. C., and the U.S. Dept. of Defense grant W81XWH-15-1-0420 to K. R. H. The authors also would like to thank the Center for Electron Microscopy and Microanalysis (CEMMA) at USC for assistance in TEM imaging.
- United States Renal Data System Coordinating Center. 2015 USRDS annual data report: Epidemiology of Kidney Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2015.Google Scholar
- Arab, J. P.; Barrera, F.; Arrese, M. Bile acids and portal hypertension. Ann. Hepatol. 2017, 16, s83–s86.Google Scholar
- Shimkets, R. A.; Warnock, D. G.; Bositis, C. M.; NelsonWilliams, C.; Hansson, J. H.; Schambelan, M.; Gill, J. R.; Ulick, S.; Milora, R. V.; Findling, J. W. et al. Liddle’s syndrome: Heritable human hypertension caused by mutations in the β subunit of the epithelial sodium channel. Cell 1994, 79, 407–414.CrossRefGoogle Scholar
- Chapman, A. B.; Devuyst, O.; Eckardt, K.-U.; Gansevoort, R. T.; Harris, T.; Horie, S.; Kasiske, B. L.; Odland, D.; Pei, Y. P.; Perrone, R. D. et al. Autosomal-dominant polycystic kidney disease (ADPKD): Executive summary from a kidney disease: Improving global outcomes (KDIGO) controversies conference. Kidney Int. 2015, 88, 17–27.CrossRefGoogle Scholar
- Liu, Y. X.; Ma, X. X.; Zheng, J.; Jia, J. Y.; Yan, T. K. Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: A meta-analysis of randomised controlled trials. BMC Nephrol. 2017, 18, 206.CrossRefGoogle Scholar
- Hamley, I. W. Amphiphiles. In Introduction to Soft Matter; Hamley, I.W., Eds.; John Wiley & Sons, Ltd.: Chichester, 2007; pp 161–220.Google Scholar
- Zavaleta, C.; Ho, D.; Chung, E. J. Theranostic nanoparticles for tracking and monitoring disease state. SLAS Technol. 2018, 23, 281–293.Google Scholar
- Boron, W. F.; Boulpaep, E. L. Medical Physiology, 3rd ed.; Elsevier: Phildelphia, PA, USA, 2016.Google Scholar
- Chung, E. J.; Pineda, F.; Nord, K.; Karczmar, G.; Lee, S. K.; Tirrell, M. Fibrin-targeting, peptide amphiphile micelles as contrast agents for molecular MRI. J. Cell Sci. Ther. 2014, 5, 181.Google Scholar
- Snanoudj, R.; Durrbach, A.; Gauthier, E.; Adams, D.; Samuel, D.; Ferlicot, S.; Bedossa, P.; Prigent, A.; Bismuth, H.; Charpentier, B. Changes in renal function in patients with familial amyloid polyneuropathy treated with orthotopic liver transplantation. Nephrol. Dial. Transplant. 2004, 19, 1779–1785.CrossRefGoogle Scholar
- Ng, C. K. F.; Chan, M. H. M.; Tai, M. H. L.; Lam, C. W. K. Hepatorenal syndrome. Clin. Biochem. Rev. 2007, 28, 11–17.Google Scholar
- Rodrigues, W. F.; Miguel, C. B.; Napimoga, M. H.; Oliveira, C. J. F.; Lazo-Chica, J. E. Establishing standards for studying renal function in mice through measurements of body size-adjusted creatinine and urea levels. BioMed Res. Int. 2014, 2014, Article ID 872827.Google Scholar